{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:36Z","timestamp":1792597596144,"version":"4.5.0"},"reference-count":21,"publisher":"MyJove Corporation","issue":"220","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/67584","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:01:06Z","timestamp":1749582066000},"source":"Crossref","is-referenced-by-count":0,"title":["High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research"],"prefix":"10.3791","author":[{"given":"Kevin","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Veith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Duro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourab","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Cajigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vasaturo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/path.5663","type":"journal-article","article-title":"Clinical and research applications of multiplexed immunohistochemistry and in situ hybridization","volume":"254","author":"McGinnis","year":"2021","unstructured":"McGinnis, L. M., Ibarra-Lopez, V., Rost, S., Ziai, J. Clinical and research applications of multiplexed immunohistochemistry and in situ hybridization. J Pathol. 254 (4), 405-417 (2021).","journal-title":"J Pathol"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","type":"journal-article","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","unstructured":"Tan, W. C. C. et al. Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Comm. 40 (4), 135-153 (2020).","journal-title":"Cancer Comm"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1002\/acg2.113","type":"journal-article","article-title":"Immunological tumor heterogeneity and diagnostic profiling for advanced and immune therapies","volume":"4","author":"Huss","year":"2021","unstructured":"Huss, R., Schmid, C., Manesse, M., Thagaard, J., Maerkl, B. Immunological tumor heterogeneity and diagnostic profiling for advanced and immune therapies. Adv Cell Gene Ther. 4 (3), e113 (2021).","journal-title":"Adv Cell Gene Ther"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-01651-y","type":"journal-article","article-title":"Kaiso (ZBTB33) subcellular partitioning functionally links LC3A\/B, the tumor microenvironment, and breast cancer survival","volume":"4","author":"Singhal","year":"2021","unstructured":"Singhal, S. K. et al. Kaiso (ZBTB33) subcellular partitioning functionally links LC3A\/B, the tumor microenvironment, and breast cancer survival. Comm Biol. 4 (1), 1-13 (2021).","journal-title":"Comm Biol"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","type":"journal-article","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","unstructured":"Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 40 (3), 289-300.e4 (2022).","journal-title":"Cancer Cell"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","type":"journal-article","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","unstructured":"Hong, D. S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med. 29 (1), 104-114 (2023).","journal-title":"Nat Med"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.modpat.2022.100032","type":"journal-article","article-title":"Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry","volume":"36","author":"Robbins","year":"2023","unstructured":"Robbins, C. J. et al. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. Mod Pathol. 36 (1), 100032 (2023).","journal-title":"Mod Pathol"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40487-023-00249-0","type":"journal-article","article-title":"Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate","volume":"12","author":"Ko","year":"2024","unstructured":"Ko, H. et al. Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? Oncol Ther. 12 (1), 13-17 (2024).","journal-title":"Oncol Ther"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2021.03.208","type":"journal-article","article-title":"How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy","volume":"32","author":"Fundytus","year":"2021","unstructured":"Fundytus, A., Booth, C. M., Tannock, I. F. How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. Ann Oncol. 32 (7), 833-836 (2021).","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-4939-8935-5_26","type":"journal-article","article-title":"An Introduction to Performing Immunofluorescence Staining","volume":"1897","author":"Im","year":"2019","unstructured":"Im, K., Mareninov, S., Diaz, M. F. P., Yong, W. H. An Introduction to Performing Immunofluorescence Staining. Method Mol Biol. 1897, 299-311 (2019).","journal-title":"Method Mol Biol"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.3390\/ijms24043086","type":"journal-article","article-title":"Multiplex Immunofluorescence: A Powerful Tool in Cancer Immunotherapy","volume":"24","author":"Sheng","year":"2023","unstructured":"Sheng, W. et al. Multiplex Immunofluorescence: A Powerful Tool in Cancer Immunotherapy. Int Mol Sci. 24 (4), 3086 (2023).","journal-title":"Int Mol Sci"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"e000155","DOI":"10.1136\/jitc-2019-000155","type":"journal-article","article-title":"The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation","volume":"8","author":"Taube","year":"2020","unstructured":"Taube, J. M. et al. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J ImmunoTher Cancer. 8 (1), e000155 (2020).","journal-title":"J ImmunoTher Cancer"},{"issue":"1","key":"ref13","first-page":"41","type":"journal-article","article-title":"A review of automated slide stainers for immunohistochemistry and in situ hybridization","volume":"40","author":"Myers","year":"2008","unstructured":"Myers, J. A review of automated slide stainers for immunohistochemistry and in situ hybridization. Medl Lab Obser. 40 (1), 41-44 (2008).","journal-title":"Medl Lab Obser"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"e005141","DOI":"10.1136\/jitc-2022-005141","type":"journal-article","article-title":"Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial","volume":"10","author":"Schwarze","year":"2022","unstructured":"Schwarze, J. K. et al. Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. J ImmunoTher Cancer. 10 (9), e005141 (2022).","journal-title":"J ImmunoTher Cancer"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","type":"journal-article","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 7 (1), 16878 (2017).","journal-title":"Sci Rep"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41379-018-0071-1","type":"journal-article","article-title":"Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms","volume":"31","author":"Koppel","year":"2018","unstructured":"Koppel, C. et al. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Mod Pathol. 31 (11), 1630-1644 (2018).","journal-title":"Mod Pathol"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/cancers12020255","type":"journal-article","article-title":"Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies","volume":"12","author":"Parra","year":"2020","unstructured":"Parra, E. R. et al. Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. Cancers. 12 (2), 255 (2020).","journal-title":"Cancers"},{"issue":"143","key":"ref18","first-page":"e58390","type":"journal-article","article-title":"Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens","author":"Surace","year":"2019","unstructured":"Surace, M. et al. Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens. J Vis Exp. (143), e58390 (2019).","journal-title":"J Vis Exp"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ceb.2013.11.003","type":"journal-article","article-title":"Changes in cell and tissue organization in cancer of the breast and colon","volume":"0","author":"Hinck","year":"2014","unstructured":"Hinck, L., N\u00e4thke, I. Changes in cell and tissue organization in cancer of the breast and colon. Curr Opin Cell Biol. 0, 87-95 (2014).","journal-title":"Curr Opin Cell Biol"},{"issue":"13","key":"ref20","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","type":"journal-article","article-title":"Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment","volume":"12","author":"Alturki","year":"2023","unstructured":"Alturki, N. A. Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment. J Clin Med. 12 (13), 4301 (2023).","journal-title":"J Clin Med"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01522-4","type":"journal-article","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","unstructured":"Sun, Q. et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Targeted Ther. 8 (1), 1-26 (2023).","journal-title":"Signal Transduct Targeted Ther"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/67584\/high-throughput-automated-multiplex-immunofluorescence-assays-for","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:16Z","timestamp":1792594816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/67584\/high-throughput-automated-multiplex-immunofluorescence-assays-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":21,"journal-issue":{"issue":"220","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3791\/67584","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}